日本語 
Pharming Group announced data from a Phase II clinical trial that assessed leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) that show immune dysregulation. The Dutch biotechnology company said the data have been accepted as a late‑breaking abstract for presentation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID). The meeting will take place on October 14–17 2026 in the Netherlands.
This development expands the investigation of leniolisib beyond activated phosphoinositide 3‑kinase delta syndrome (APDS) the immune disorder for which leniolisib is already approved in several markets, including Japan.
Expanding Leniolisib Beyond APDS
Leniolisib is a PI3Kδ inhibitor designed to modulate a signaling pathway that is involved in immune‑cell function. Pharming is studying whether leniolisib can address dysregulation in a group of genetically identifiable PIDs.
The Phase II program includes conditions that are associated with altered PI3Kδ signaling, such as ALPS‑FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency. Pharming previously described these conditions as having a patient population than APDS.
The company has been conducting two Phase II trials that evaluate leniolisib in PIDs. One trial focuses on identifiable immune dysregulation while the other involves common variable immunodeficiency (CVID). Enrollment in both programs has been completed. Readouts are expected during the quarter of 2026.
The latest announcement provides an update, for the genetically identifiable PID study. Detailed findings are expected during the presentation.
Why the Results Matter for Rare-Disease Drug Development
Rare diseases usually affect a few people and can show big differences in genetics and how they show symptoms. To make medicines for these diseases we need to find the biological pathways that link different disorders.
The PI3Kδ pathway is one of those targets. By looking at leniolisib in PIDs that have immune dysregulation Pharming is checking if a therapy that works for APDS can also help other similar disorders.
The new results do not make leniolisib an approved drug for those wider uses. Pharming has said that we do not yet know if leniolisib is safe or effective for PIDs with dysregulation outside of APDS.
Clinical trials and regulatory checks will be needed before we can think about using leniolisib more widely.
Growing Importance of Precision Medicine
This work also shows how genetic diagnosis matters in treating diseases. When we can identify the changes in PIDs we can see how the immune system is altered. That lets scientists look at treatments based on the biology not just the symptoms.
This way of doing things is becoming more and more important for precision medicine. Genetic tests, molecular profiles and patient records help researchers find groups of patients who might get better from targeted treatments.
For drug makers this means they need skills in genomics, biomarker work, managing trial data and smart data analysis. Linking a patient’s genetics to how they respond to treatment is also vital when planning studies for diseases, with few patients.
Implications for Japan’s Biotech Sector
The development is relevant to Japans biotechnology and healthcare technology sectors particularly as the country expands its focus on diseases and precision medicine.
Pharming has already received approval for Joenja, the brand name for leniolisib for the treatment of APDS in patients aged 4 years and older. The company describes it as a targeted treatment for APDS with its mechanism centered on PI3Kδ signaling.
The broader Phase II program could therefore be watched closely in Japan as research explores whether the same therapeutic mechanism may eventually have relevance to immune disorders.
For pharmaceutical companies, universities and diagnostic providers the development illustrates the potential value of combining genetic testing with targeted drug development. It also reinforces the importance of identification specialist clinical networks and data infrastructure in rare-disease research.
AI and Data Could Support the Next Stage
As rare-disease research becomes data intensive technologies such as AI, genomic analysis and clinical-data platforms could play a larger role in identifying eligible patients and analyzing treatment responses.
For diseases affecting populations finding suitable trial participants can be particularly challenging. Digital patient registries, genetic databases and clinical decision‑support systems could help researchers identify patients whose biological characteristics match research programs.
Also Read: Four Japanese Researchers Win Lasker Awards for Medical Innovation
AI could also support the analysis of genomic and clinical datasets although clinical validation and regulatory oversight remain essential when such technologies are used in drug development.
Pharmings latest leniolisib update therefore reflects more than progress for one rare-disease program. It illustrates a pharmaceutical shift toward mechanism-based treatments, genetic patient identification and precision medicine.
The detailed Phase II findings at ESID 2026 will provide information on the clinical results. Until further data and regulatory evaluation are completed the potential use of leniolisib in these PIDs remains an area of clinical investigation rather, than an established treatment indication.
English